课题基金 / 基金详情

The role of IL-6, HGF and TGFβ_1 in biliary epithelial cells carcinogenesis

The role of IL-6, HGF and TGFβ_1 in biliary epithelial cells carcinogenesis
IL-6、HGF和TGFβ_1在胆管上皮细胞癌变中的作用
批准号:
12671275
负责人:
YOKOMURO Shigeki
金额:
$1.86万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2002

项目摘要

项目成果

YOKOMURO Shigeki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Intraheptatic chollagiocarcinoma (CC) and other cancers of the biliary tree, including the gallbladder, are often associated with non-neoplastic inflammatory diseases of the biliary tree, such as sclerosing cholangitis, clonorchiasis, and hepatolithiasis. These diseases also involve reparative, non-neoplastic biliary epithelial cell (BEC) proliferation. Unfortunately, although a significant number of biliary tract cancers arise under predictable conditions, they carry a poor prognosis because of difficulties in establishing the diagnosis before the tumors reach a noncurative stage. Earlier diagnosis and attempts at curative therapy will require a better understanding of the molecular mechanisms controlling reparative and cancerous BEC growth and the steps involved in a transition between the 2 processes. During non-neoplastic BEC repair like that seen with obstructive cholangiopathy, competing mitogenic and mitoinhibitory influences action on BECs, largely in a paracrine fashion, are a … More ccompanied by activation of periductal myofibroblasts and fibrogenesis. For example, the first several days to weeks afte biliary obstraction are characterized by explosive BEC proliferation. This is associated with up-regulation of hepatocyte growth factor (HGF) and interleukin 6 (IL-6) in the peribiliary stromal and hematolymphoid cells, and these same mediators stimulate non-neoplastic BEC DNA synthesis, in vitro. However, if the obstruction persists, BEC proliferation returns to near beseline levels and progressive fibrogenesis ensues. This occurs coincidently with tht induction of mitoinhibitory and fibrogenic growth factors, such as fibroblast growth factor and the TGF-b family of mitoinhibitory cytokines, including TGF-b1 and activin A. Receptros for these mitogens or mitoinhibitors, respectivily, are upregulated on the sruface of the BEC during successive stages of the response. The transition from reactive BEC to CC is accompanied by alterations that favor continued growth over mitoinhibition and apoptosis. Thus, malignancies can circumvent the effect s of mediators that inhibit growth or induce apoptosis, or acquire the ability to synthesize and secrete their own growth factor(s), superseding the normal paractine signaling with autocrine pathways. Less
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Shigeki Yokomuro: "Growth Control of Human Biliary Epithelial Cells by IL-6, HGF, TGFB, and Activin A"Hepatology. 32. 26-35 (2000)
Shigeki Yokomuro:“IL-6、HGF、TGFB 和激活素 A 对人胆管上皮细胞的生长控制”肝病学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Shigeki Yokomuro: "Growth Control of Human Biliary Epithelial Cells by IL-6, HGF, TGFβ_1 and Activin."Hepatology. 32. 26-35 (2000)
Shigeki Yokomuro:“IL-6、HGF、TGFβ_1 和激活素对人胆管上皮细胞的生长控制”,《肝病学》32. 26-35 (2000)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Shigeki Yokomuro: "Growth Control of human biliary epithelial cells by IL-6 HGF, TGFβ1 and Activin A."Hepatology. 32(1). 26-35 (2000)
Shigeki Yokomuro:“IL-6 HGF、TGFβ1 和激活素 A 对人胆管上皮细胞的生长控制”,Hepatology 32(1) (2000)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
The effect for C-reactive protein (CRP) for sever sepsis
  • 批准号:
    16K11424
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $3.08万
  • 财政年份:
    2016
  • 负责人:
    YOKOMURO Shigeki
  • 依托单位:
Application of IL-6 HGF, TGF beta 1 for a bile duct cancer treatment.
  • 批准号:
    15591450
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.11万
  • 财政年份:
    2003
  • 负责人:
    YOKOMURO Shigeki
  • 依托单位:
国内基金
海外基金
早期滋养型肠内营养联合益生菌对重症卒中患者喂养耐受性及TNF-α/IL-6水平的影响研究
七氟烷通过调控IL-6/FSP1轴抑制心肌铁死亡减轻心肌缺血再灌注损伤的机制研究
  • 批准号:
    JCZRLH202601296
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
盐酸小檗碱抑制NF-κB/IL-6/STAT3信号通路重塑免疫微环境并增敏肺癌免疫治疗的研究
  • 批准号:
    JCZRLH202600985
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
双歧杆菌与消退素RvD1协同调控IL-6/STAT3/Notch信号轴介导结肠癌EMT及免疫调节的机制研究
  • 批准号:
    JCZRLH202601410
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位: